Unfit individuals also have the choice of venetoclax as well as obinutuzumab (VO) as frontline therapy. This relies on the period III trial that compared VO with ClbO in aged/unfit patients.113 VO was exceptional in terms of reaction fee and progression-cost-free survival, and experienced a comparable protection profile. In this https://owenm420gow7.azuria-wiki.com/user